| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 07/08/2004 | US20040132679 Induction of pancreatic islet formation |
| 07/08/2004 | US20040132678 Recombinant double-stranded RNA phage, and use of the same |
| 07/08/2004 | US20040132676 Polynucleotide formulation for enhanced intracellular transfer |
| 07/08/2004 | US20040132675 Drug deliverying an angiogenesis inhibitor, reduce the side effect of chemotherapy and radiation therapy, increase red blood cells; truncated, soluble Flk1/KDR receptor, recombinant protein; inhibitor of vascular endothelial growth factor |
| 07/08/2004 | US20040132674 Regulatory sequence for the specific expression in dendritic cells and uses thereof |
| 07/08/2004 | US20040132191 Yeasts transformed by genes enhancing their cold stress tolerance |
| 07/08/2004 | US20040132190 Comprises genetically engineered adenoviral coding therapeutic agents as marker protein for use as gene transfer/drug delivery tool in cardiac diagnostic catheterization |
| 07/08/2004 | US20040132181 Trans-splicing mediated photodynamic therapy |
| 07/08/2004 | US20040132179 Treatment of t cell disorders |
| 07/08/2004 | US20040132178 Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
| 07/08/2004 | US20040132163 Biological materials and uses thereof |
| 07/08/2004 | US20040132139 Comprises nucleotide sequences coding protein with antiproliferative and viricidal activity for use in treatment and prevention of cancer, nervous system, bone and autoimmune disorders |
| 07/08/2004 | US20040132063 Antisense modulation of microsomal prostaglandin E2 synthase expression |
| 07/08/2004 | US20040132057 Tumor necrosis related receptor,TR7 |
| 07/08/2004 | US20040132053 Sphingosine kinase enzyme |
| 07/08/2004 | US20040132038 Membrane protein for use as diagnostic tool in the detection and prevention of cell proliferative, cardiovascular, skin, nervous system, respiratory and metabolic disorders |
| 07/08/2004 | US20040132028 Collection of repeat proteins comprising repeat modules |
| 07/08/2004 | US20040132020 Novel enzyme gene and its expression product |
| 07/08/2004 | US20040132007 Modified virus |
| 07/08/2004 | US20040131666 Liposome encapsulating active materials |
| 07/08/2004 | US20040131641 Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 07/08/2004 | US20040131638 Novel composition |
| 07/08/2004 | US20040131634 Neisseria lactoferrin binding protein |
| 07/08/2004 | US20040131605 Therapy for genetic disorders; purification by chromatography |
| 07/08/2004 | US20040131602 Methods for enhancing graft survival by modulating heme oxygenase activity |
| 07/08/2004 | US20040131601 Injection of bone marrow-derived cells and medium for angiogenesis |
| 07/08/2004 | US20040131600 Method of preventing adhesions by apoptosis of adhesion peritoneal cells |
| 07/08/2004 | US20040131595 Treating carcinoid neoplasms with therapeutic viruses |
| 07/08/2004 | US20040131593 Neuronal gene transfer |
| 07/08/2004 | US20040131590 Anticancer agents |
| 07/08/2004 | US20040131585 Identification and use og human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 07/08/2004 | US20040131582 Sealing wounds; wound healibng agents; sealing tissues; crosslinking |
| 07/08/2004 | DE10257771A1 Inhibierung der HIV Replikation durch Expression von 'late domain' Peptiden in Zielzellen Inhibition of HIV replication by expression of 'late domain' peptides in target cells |
| 07/08/2004 | DE10257770A1 Expression von Peptiden des zytoplasmatischen Bereiches von HIV-gp41 zur Hemmung viraler Infektionen Expression of peptides of the cytoplasmic region of HIV gp41 to inhibit viral infections |
| 07/08/2004 | DE10257421A1 Regulatorische Elemente im 5'-Bereich des VR1-Gens Regulatory elements in the 5 'region of the VR1 gene |
| 07/08/2004 | DE10221411B4 Rekombinantes Fowlpox-Virus Recombinant fowlpox virus |
| 07/08/2004 | CA2551172A1 Genetic therapy and genetic modification using neocentromeric minichromosomes |
| 07/08/2004 | CA2510381A1 Detection of small nucleic acids |
| 07/08/2004 | CA2510229A1 Production of alvac on avian embryonic stem cells |
| 07/08/2004 | CA2505374A1 Melusin, a muscle specific protein, as a drug target for prevention and treatment of heart failure |
| 07/08/2004 | CA2501975A1 Recombinant virus production for the manufacturing of vaccines |
| 07/07/2004 | EP1435387A1 The oncolytic microorganisms expressing hsp and uses thereof |
| 07/07/2004 | EP1435243A2 Methods of alleviating cancer symtoms |
| 07/07/2004 | EP1435232A1 Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 07/07/2004 | EP1434885A2 21132, a human g-protein coupled receptor family member and uses therefor |
| 07/07/2004 | EP1434884A2 Single nucleotide polymorphisms predicting cardiovascular disease |
| 07/07/2004 | EP1434882A1 Aptamers containing sequences of nucleic acids or nucleic acid analogues bound homologously, or in novel complexes |
| 07/07/2004 | EP1434878A2 Nucleic acid constructs capable of high efficiency delivery of polynucleotides into dna containing organelles and methods of utilizing same |
| 07/07/2004 | EP1434876A1 Expression profiling in the intact human heart |
| 07/07/2004 | EP1434868A2 Adenoviral vector system |
| 07/07/2004 | EP1434862A2 Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the cns |
| 07/07/2004 | EP1434855A2 Adipose-derived stem cells and lattices |
| 07/07/2004 | EP1434794A2 Fragments of heat shock proteins and their use |
| 07/07/2004 | EP1434603A2 Method of treatment using ligand-immunogen conjugates |
| 07/07/2004 | EP1434602A2 Cpg formulations and related methods |
| 07/07/2004 | EP1434598A2 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis |
| 07/07/2004 | EP1434597A1 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 07/07/2004 | EP1354055A4 Neocentromere-based mini-chromosomes or artificial chromosomes |
| 07/07/2004 | EP1083951A4 Methods of delivering aerosolized polynucleotides to the respiratory tract |
| 07/07/2004 | CN1511040A Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 07/07/2004 | CN1510137A Gene identification |
| 07/07/2004 | CN1510130A Attenuated cattle viral diarrhoea virus |
| 07/07/2004 | CN1509764A Preparation of target gene virus medicine against cancers |
| 07/07/2004 | CN1156578C Pistal-type gas gene gun |
| 07/07/2004 | CN1156309C Equipment utilizing electric pulse to transfer gene |
| 07/06/2004 | US6759518 Single-chain multiple antigen-binding molecule, its preparation and use |
| 07/06/2004 | US6759516 Methods of identifying antigen gene sequences |
| 07/06/2004 | US6759394 Cancer gene therapy based on translational control of a suicide gene |
| 07/06/2004 | US6759393 Growth hormone and growth hormone releasing hormone compositions |
| 07/06/2004 | US6759385 Methods to treat undesirable immune responses |
| 07/06/2004 | US6759242 Low oxygen culturing of neural crest stem cells and methods of use |
| 07/06/2004 | US6759236 For gene therapy of restricted areas e.g. tumors |
| 07/06/2004 | US6759211 For cancer use in therapy |
| 07/06/2004 | US6759210 Compositions and methods for the treatment and diagnosis of cardiovascular disease using fehd545 as a target |
| 07/06/2004 | US6759201 Method of identifying a neural progenitor cell by evaluating expression of daedalos |
| 07/06/2004 | US6759050 Stable; recombinant adeno-associated virus (raav) virions that provide protection against loss of transduceability due to manipulation, storage, transport; a dihydric or polyhydric alcohol; polyethylene glycol, propylene glycol, sorbitol |
| 07/06/2004 | US6759046 Peptides |
| 07/06/2004 | US6759044 Cryptopain antibodies for prophylaxis, treatment, diagnosis and detection of Cryptosporidium species |
| 07/06/2004 | US6759038 Evaluating drug for prevention of cancer propagation; administer drug to vertebrate, monitor cancer propagation by fluoresence, compare to control, decrease in fluoresence indicates prevention of tumor propagation |
| 07/06/2004 | US6759037 Compositions and methods for treating diabetes |
| 07/06/2004 | US6759036 Fibrocyte-base vaccine formulations |
| 07/06/2004 | CA2071510C 2' modified oligonucleotides |
| 07/01/2004 | WO2004056080A1 Endothelial cell specifically binding peptides |
| 07/01/2004 | WO2004055196A2 Method for identifying risk of breast cancer and treatments thereof |
| 07/01/2004 | WO2004055186A1 Guanosine triphosphate-binding protein-coupled receptor |
| 07/01/2004 | WO2004055180A1 Method of diagnosis of obesity |
| 07/01/2004 | WO2004055174A1 Culture medium composition, culture method, and myoblasts obtained, and their uses |
| 07/01/2004 | WO2004055167A2 Alphavirus particles and methods for preparation |
| 07/01/2004 | WO2004055166A2 Multi-antigenic alphavirus replicon particles and methods |
| 07/01/2004 | WO2004055161A2 Large scale production of packaged alphavirus replicons |
| 07/01/2004 | WO2004055159A2 Identification of oligonucleotides for the capture, detection and quantitation of west nile virus |
| 07/01/2004 | WO2004055056A1 Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
| 07/01/2004 | WO2004054969A2 Sacromastigophoric therapeutic agent delivery system |
| 07/01/2004 | WO2004054620A1 Induction of tolerance through oral administration of a therapeutic agent coupled to a transporting agent |
| 07/01/2004 | WO2004054618A1 Drugs for inhibiting rejection reaction in tissue transplanted into mammalian tissue and method of treating diabetes using the same |
| 07/01/2004 | WO2004054512A2 Therapeutic retroviral vectors for gene therapy |
| 07/01/2004 | WO2004054502A2 Modulation of tek expression |
| 07/01/2004 | WO2004054428A2 Nor-1 (neuron-derived orphan receptor-1), novel diagnostic and therapeutic target for cardiovascular diseases |
| 07/01/2004 | WO2004054356A2 Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent |
| 07/01/2004 | WO2004048519A3 Treatment of mammalian reaction to ige interactions |